# AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-tagrisso-recommended-for-approval-in-the-eu-for-nsclc-treatment/4121158994
- Published: 2024-06-03T07:27:26+01:00
- Author: Amilia Stone

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Tagrisso_ (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy
has been recommended for approval in the European Union (EU) for 1st-line treatment
of adult patients with locally advanced or metastatic epidermal growth factor receptor-
mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions
or exon 21 (L858R) mutations.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) based its positive opinion on the results from the FLAURA2 Phase III
trial, which were also published in The New England Journal of Medicine_. _

Results showed _Tagrisso_ with the addition of chemotherapy reduced the risk of 
disease progression or death by 38% compared to _Tagrisso_ monotherapy, which is
the 1st-line global standard of care (hazard ratio [HR] 0.62; 95% confidence interval[
CI] 0.49-0.79; p<0.0001). Median progression-free survival (PFS) by investigator
assessment was 25.5 months for patients treated with _Tagrisso_ plus chemotherapy,
an 8.8-month improvement versus _Tagrisso_ monotherapy (16.7 months).

While overall survival (OS) remained immature at the second interim analysis (41%
maturity), an encouraging trend towards an OS benefit was observed with _Tagrisso_
plus chemotherapy versus _Tagrisso_ alone (HR 0.75; 95% CI 0.57-0.97). The trial
continues to assess OS as a key secondary endpoint.

Each year in Europe, there are more than 450,000 people diagnosed with lung cancer.
^(1) Among those with NSCLC, the most common form of lung cancer, about 10-15% of
patients in Europe have tumours with an EGFR mutation.^(2,3) Additionally, the majority
of patients with NSCLC are diagnosed with advanced disease.^(4)

> **David Planchard, MD, PhD, thoracic oncologist at Gustave Roussy Institute of
> Oncology and principal investigator for the trial, said**: “The FLAURA2 results
> build on the established efficacy of osimertinib monotherapy in patients with 
> EGFR-mutated lung cancer, demonstrating a meaningful nine-month improvement in
> progression-free survival with the addition of chemotherapy. Today’s positive 
> recommendation is a vital step towards providing patients in Europe with an additional
> treatment option capable of extending the time before their disease progresses.
> This expands on the already approved use of osimertinib as monotherapy, providing
> physicians with options to tailor treatments that best suit their patients’ specific
> disease needs.”

> **Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said**:“
> Today’s news reinforces the importance of _Tagrisso_ as the backbone therapy in
> EGFR-mutated lung cancer. If approved in Europe, patients will have the option
> to be treated with _Tagrisso_ alone, or with chemotherapy, which is especially
> important when caring for patients whose disease has spread to the brain or those
> with L858R mutations.”   

The safety profile of _Tagrisso_ plus chemotherapy was generally manageable and 
consistent with the established profiles of the individual medicines. Adverse event(
AE) rates were higher in the _Tagrisso_ plus chemotherapy arm, driven by well-characterised
chemotherapy-related AEs. Discontinuation rates of _Tagrisso_ due to AEs were 11%
for _Tagrisso _plus chemotherapy and 6% for monotherapy.   

_Tagrisso_ is approved as monotherapy in more than 100 countries including in the
US, EU, China and Japan. Approved indications include for 1st-line treatment of 
patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic
EGFR T790M mutation-positive NSCLC, and adjuvant treatment of early-stage EGFRm 
NSCLC. _Tagrisso_ with the addition of chemotherapy is also approved in the US and
several other countries for the 1st-line treatment of patients with locally advanced
or metastatic EGFRm NSCLC.     

**_Tagrisso_**

_Tagrisso_ (osimertinib) is a third-generation, irreversible EGFR-TKI with proven
clinical activity in NSCLC, including against central nervous system (CNS) metastases.
_Tagrisso_ (40mg and 80mg once-daily oral tablets) has been used to treat nearly
800,000 patients across its indications worldwide and AstraZeneca continues to explore
_Tagrisso_ as a treatment for patients across multiple stages of EGFRm NSCLC.

There is an extensive body of evidence supporting the use of _Tagrisso_ in EGFRm
NSCLC. _Tagrisso_ is the only targeted therapy to improve patient outcomes in early-
stage disease in the ADAURA Phase III trial, locally advanced stages in the LAURA
Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2
Phase III trial. 

As part of AstraZeneca’s ongoing commitment to treating patients as early as possible
in lung cancer, _Tagrisso_ is also being investigated in the neoadjuvant setting
in the NeoADAURA Phase III trial with results expected later this year and in the
early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.

The Company is also researching ways to address tumour mechanisms of resistance 
through the SAVANNAH and ORCHARD Phase II trials, and the SAFFRON Phase III trial,
which test _Tagrisso_ plus savolitinib, an oral, potent and highly selective MET
TKI, as well as other potential new medicines.

Share on:
